Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Research Abstract |
Osteoclasts are unique bone resorbing cells, and thus are therapeutic targets to treat bone diseases such as osteoporosis. We found that B lymphocyte induced maturation protein 1 (Blimp1), a transcriptional repressor, was required for osteoclastogenesis. Although Blimp1-null mutant mice are embryonic lethal, Blimp1 conditional knockout at an adult stage by a Cre/loxP system did not promote lethal adverse effects in mice, while resulted in significant inhibition of osteoclast formation with increased bone mass. Thus, Blimp1 was considered as a therapeutic target to treat skeletal diseases such as osteoporosis (J Biol Chem 2012).
|